Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg

Ahmedabad, India, 25 November, 2025

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg).

Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks. Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh.

Verapamil Hydrochloride Extended-Release Tablets had annual sales of USD 24.5 mn in the United States (IQVIA MAT Sept-2025).

The group now has 428 approvals and has so far filed 487* ANDAs since the commencement of the filing process in FY 2003-04.

*(*As on 30-Sept-25)*

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878